{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:08:51Z","timestamp":1791248931708,"version":"4.1.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.phrs.2018.07.006","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T15:16:06Z","timestamp":1530976566000},"page":"268-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0153-3493","authenticated-orcid":false,"given":"Nitin","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0865-2823","authenticated-orcid":false,"given":"Congcong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.07.006_bib0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3181\/0707-MR-190","article-title":"Mechanisms of fibrogenesis","volume":"233","author":"Kisselevaand","year":"2008","journal-title":"Exp. Boil. Med. (Maywood, NJ)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/ATVBAHA.110.213850","article-title":"Mechanisms of resolution of inflammation: a focus on cardiovascular disease","volume":"31","author":"Maskrey","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0015","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ni.3731","article-title":"The multiple pathways to autoimmunity","volume":"18","author":"Theofilopoulos","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0020","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa040967","article-title":"Inflammatory markers and the risk of coronary heart disease in men and women","volume":"351","author":"Pai","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.006_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/HYPERTENSIONAHA.110.163576","article-title":"Inflammation, immunity, and hypertension","volume":"57","author":"Harrison","year":"2011","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0030","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJMc071324","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus","volume":"357","author":"Malozowskiand","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.07.006_bib0035","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00467-008-1046-0","article-title":"Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease","volume":"24","author":"Silverstein","year":"2009","journal-title":"Pediatric Nephrol. (Berlin, Germany)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0040","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0895-4356(01)00502-9","article-title":"C-reactive protein and myocardial infarction","volume":"55","author":"Sakkinen","year":"2002","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/jmcc.1999.1049","article-title":"Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes","volume":"32","author":"Stefanadis","year":"2000","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/01.HYP.0000107777.91185.89","article-title":"Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction","volume":"43","author":"Yang","year":"2004","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0055","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1161\/01.HYP.37.2.794","article-title":"Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats","volume":"37","author":"Peng","year":"2001","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0060","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3171\/2016.3.JNS152699","article-title":"Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline","volume":"126","author":"Zhang","year":"2017","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.phrs.2018.07.006_bib0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0163-7258(79)90029-9","article-title":"Renin-angiotensin system in hypertension","volume":"7","author":"Swales","year":"1979","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.07.006_bib0070","doi-asserted-by":"crossref","first-page":"9177","DOI":"10.1016\/S0021-9258(17)39349-3","article-title":"Role of calcium fluxes in the sustained phase of angiotensin II-mediated aldosterone secretion from adrenal glomerulosa cells","volume":"260","author":"Kojima","year":"1985","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.07.006_bib0075","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1073\/pnas.93.18.9960","article-title":"Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense","volume":"93","author":"Iyer","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.phrs.2018.07.006_bib0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ki.1986.14","article-title":"Renal kallikrein-kinin system","volume":"29","author":"Scicliand","year":"1986","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2018.07.006_bib0085","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.07.006_bib0090","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.phrs.2018.07.006_bib0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1113\/expphysiol.2012.067165","article-title":"Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in wistar-Kyoto rats and spontaneously hypertensive rats","volume":"98","author":"Lo","year":"2013","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0100","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1073\/pnas.86.3.779","article-title":"Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure","volume":"86","author":"Lenfant","year":"1989","journal-title":"PNAS"},{"key":"10.1016\/j.phrs.2018.07.006_bib0105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1196\/annals.1415.024","article-title":"Thymosin beta-NB is the human isoform of rat thymosin beta15","volume":"1112","author":"Banyard","year":"2007","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.phrs.2018.07.006_bib0110","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jmb.2009.02.026","article-title":"The mouse thymosin beta15 gene family displays unique complexity and encodes a functional thymosin repeat","volume":"387","author":"Dhaese","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0115","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cm.20371","article-title":"The beta-thymosins: intracellular and extracellular activities of a versatile actin binding protein family","volume":"66","author":"Mannherzand","year":"2009","journal-title":"Cell Motil. Cytoskeleton"},{"key":"10.1016\/j.phrs.2018.07.006_bib0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0014-5793(90)81322-F","article-title":"Involvement of thymosin beta 4 and endoproteinase asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system","volume":"274","author":"Grillon","year":"1990","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2018.07.006_bib0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0301-472X(00)00634-2","article-title":"Bone marrow endothelial cells secrete thymosin beta4 and AcSDKP","volume":"29","author":"Huangand","year":"2001","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1749-6632.2010.05488.x","article-title":"Overexpression of the natural tetrapeptide acetyl-N-ser-asp-lys-pro derived from thymosin beta4 in neoplastic diseases","volume":"1194","author":"Liu","year":"2010","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"June (6)","key":"10.1016\/j.phrs.2018.07.006_bib0135","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/HYPERTENSIONAHA.118.10952","article-title":"Thymosin beta4 deficiency exacerbates renal and cardiac injury in angiotensin-II-induced hypertension","volume":"71","author":"Kumar","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2018.07.006_bib0140","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1476-5381.2010.01146.x","article-title":"Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner","volume":"163","author":"Myohanen","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0145","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/01.HYP.0000126172.01673.84","article-title":"Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP","volume":"43","author":"Cavasin","year":"2004","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0092-8674(00)81416-6","article-title":"Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis","volume":"94","author":"Fulop","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.07.006_bib0155","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/138920308783565723","article-title":"Structure, function and biological relevance of prolyl oligopeptidase","volume":"9","author":"Szeltnerand","year":"2008","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.phrs.2018.07.006_bib0160","doi-asserted-by":"crossref","first-page":"F1026","DOI":"10.1152\/ajprenal.00562.2015","article-title":"The anti-inflammatory peptide Ac-SDKP is released from thymosin-beta4 by renal meprin-alpha and prolyl oligopeptidase","volume":"310","author":"Kumar","year":"2016","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0014-5793(91)81062-D","article-title":"Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin beta 4 in mouse tissues","volume":"289","author":"Pradelles","year":"1991","journal-title":"FEBS Lett."},{"key":"10.1016\/j.phrs.2018.07.006_bib0170","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.4049\/jimmunol.172.7.4510","article-title":"Deletion of the mouse meprin beta metalloprotease gene diminishes the ability of leukocytes to disseminate through extracellular matrix","volume":"172","author":"Crisman","year":"2004","journal-title":"Journal of immunology (Baltimore, Md: 1950)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0175","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1369\/0022155412453051","article-title":"Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors","volume":"60","author":"Myohanen","year":"2012","journal-title":"J. histochem. Cytochem."},{"key":"10.1016\/j.phrs.2018.07.006_bib0180","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/sj.jid.5700675","article-title":"The alpha and beta subunits of the metalloprotease meprin are expressed in separate layers of human epidermis, revealing different functions in keratinocyte proliferation and differentiation","volume":"127","author":"Becker-Pauly","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0185","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00418-008-0468-x","article-title":"Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues","volume":"130","author":"Myohanen","year":"2008","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0190","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0022-3565(24)35199-7","article-title":"Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-ser-asp-lys-pro in rats","volume":"291","author":"Junot","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Pt 1","key":"10.1016\/j.phrs.2018.07.006_bib0195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1242\/jcs.113.1.113","article-title":"Source, catabolism and role of the tetrapeptide N-acetyl-ser-asp-lys-pro within the testis","volume":"113","author":"Stephan","year":"2000","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.phrs.2018.07.006_bib0200","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/375146a0","article-title":"Male-female differences in fertility and blood pressure in ACE-deficient mice","volume":"375","author":"Krege","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.07.006_bib0205","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1073\/pnas.95.5.2552","article-title":"Angiotensin-converting enzyme and male fertility","volume":"95","author":"Hagaman","year":"1998","journal-title":"PNAS"},{"key":"10.1016\/j.phrs.2018.07.006_bib0210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0005-2744(71)90142-2","article-title":"Concentrations of angiotensin-converting enzyme in tissues of the rat","volume":"250","author":"Cushmanand","year":"1971","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2018.07.006_bib0215","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0026-895X(25)08912-6","article-title":"Two binding sites on angiotensin-converting enzyme: evidence from radioligand binding studies","volume":"42","author":"Perich","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0220","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.mnh.0000441047.13912.56","article-title":"Renal angiotensin-converting enzyme and blood pressure control","volume":"23","author":"Bernstein","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.phrs.2018.07.006_bib0225","doi-asserted-by":"crossref","first-page":"16754","DOI":"10.1016\/S0021-9258(19)84769-5","article-title":"Structure of testicular angiotensin-converting enzyme. A segmental mosaic isozyme","volume":"264","author":"Kumar","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"Pt 2","key":"10.1016\/j.phrs.2018.07.006_bib0230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/bj2960373","article-title":"Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline","volume":"296","author":"Rieger","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2018.07.006_bib0235","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1074\/jbc.270.8.3656","article-title":"The hemoregulatory peptide N-acetyl-ser-asp-lys-pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme","volume":"270","author":"Rousseau","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.07.006_bib0240","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1172\/JCI118484","article-title":"Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline","volume":"97","author":"Azizi","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2018.07.006_bib0245","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0022-3565(24)38267-9","article-title":"In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis","volume":"289","author":"Junot","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2018.07.006_bib0250","doi-asserted-by":"crossref","first-page":"e88001","DOI":"10.1371\/journal.pone.0088001","article-title":"A novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP","volume":"9","author":"Danilov","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2018.07.006_bib0255","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1021\/jm00170a012","article-title":"Synthesis and activity of NAcSerAspLysPro analogues on cellular interactions between T-cell and erythrocytes in rosette formation","volume":"33","author":"Thierry","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.07.006_bib0260","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/mol.51.6.1070","article-title":"Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I","volume":"51","author":"Michaud","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0265","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0022-3565(25)21322-2","article-title":"Single-domain angiotensin I converting enzyme (kininase II): characterization and properties","volume":"279","author":"Deddish","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2018.07.006_bib0270","doi-asserted-by":"crossref","first-page":"13742","DOI":"10.1038\/srep13742","article-title":"Structural basis of Ac-SDKP hydrolysis by angiotensin-I converting enzyme","volume":"5","author":"Masuyer","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2018.07.006_bib0275","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2353\/ajpath.2010.081127","article-title":"Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury","volume":"177","author":"Li","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0280","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.96.8.4330","article-title":"RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites","volume":"96","author":"Dive","year":"1999","journal-title":"PNAS"},{"key":"10.1016\/j.phrs.2018.07.006_bib0285","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1042\/CS20130403","article-title":"Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors","volume":"126","author":"Douglas","year":"2014","journal-title":"Clin. Sci. (Lond., Engl.: 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0290","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0022-3565(24)29576-8","article-title":"RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-ser-asp-lys-pro with no effect on angiotensin I hydrolysis","volume":"297","author":"Junot","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2018.07.006_bib0295","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.HYP.33.3.879","article-title":"Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans","volume":"33","author":"Azizi","year":"1999","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0300","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jpba.2010.10.009","article-title":"Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry","volume":"54","author":"Inoue","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.phrs.2018.07.006_bib0305","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1248\/bpb.b13-00992","article-title":"Significant decrease in plasma N-acetyl-seryl-aspartyl-lysyl-proline level in patients with end stage renal disease after kidney transplantation","volume":"37","author":"Suzuki","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.phrs.2018.07.006_bib0310","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/HJH.0b013e328364f5de","article-title":"Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients","volume":"31","author":"Kwakernaak","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.07.006_bib0315","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0090-9556(25)08426-0","article-title":"Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis","volume":"22","author":"Ezan","year":"1994","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2018.07.006_bib0320","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1210\/edrv-7-1-95","article-title":"Pharmacokinetics of gonadotropin-releasing hormone and its analogs","volume":"7","author":"Handelsmanand","year":"1986","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phrs.2018.07.006_bib0325","first-page":"51","article-title":"Thyrotropin-releasing hormone degradation in patients with insulin dependent diabetes mellitus. Effects of metabolic control","volume":"3","author":"Duntas","year":"1991","journal-title":"Thyroidology"},{"key":"10.1016\/j.phrs.2018.07.006_bib0330","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(99)00439-8","article-title":"Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure","volume":"34","author":"Struthers","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0335","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ijcard.2016.07.164","article-title":"Dose-effect relationship of perindopril 10, 14 and 20mg assessed by urine and plasma AcSDKP levels in mildly sodium-depleted healthy volunteers","volume":"222","author":"Monge","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0340","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.HYP.30.5.1015","article-title":"High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition","volume":"30","author":"Azizi","year":"1997","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0345","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1046\/j.1440-1681.2001.03560.x","article-title":"Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline","volume":"28","author":"Azizi","year":"2001","journal-title":"Clin. Exp. Pharmacol. Phys."},{"key":"10.1016\/j.phrs.2018.07.006_bib0350","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114844","article-title":"An insertion\/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels","volume":"86","author":"Rigat","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2018.07.006_bib0355","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1097\/01.ASN.0000030142.80452.11","article-title":"Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake","volume":"13","author":"Azizi","year":"2002","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.phrs.2018.07.006_bib0360","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2337\/dc06-0255","volume":"29","author":"Azizi","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2018.07.006_bib0365","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/ajkd.2001.26839","article-title":"Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements","volume":"38","author":"Le Meur","year":"2001","journal-title":"Am. J. kidney Dis."},{"key":"10.1016\/j.phrs.2018.07.006_bib0370","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1161\/CIRCULATIONAHA.105.549121","article-title":"Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure","volume":"112","author":"van der Meer","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.07.006_bib0375","doi-asserted-by":"crossref","first-page":"15946","DOI":"10.1074\/jbc.M400149200","article-title":"Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice","volume":"279","author":"Fuchs","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.07.006_bib0380","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ncpcardio0449","article-title":"The hematopoietic system: a new niche for the renin-angiotensin system","volume":"3","author":"Hubert","year":"2006","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2018.07.006_bib0385","doi-asserted-by":"crossref","first-page":"838","DOI":"10.2337\/diabetes.54.3.838","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db\/db mice","volume":"54","author":"Shibuya","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2018.07.006_bib0390","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1172\/JCI10557","article-title":"Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice","volume":"106","author":"Cole","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2018.07.006_bib0395","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1161\/CIRCULATIONAHA.104.528695","article-title":"Angiotensin-converting enzyme inhibitors: a new mechanism of action","volume":"112","author":"Peng","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.07.006_bib0400","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/01.HYP.0000258406.66954.4f","article-title":"Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension","volume":"49","author":"Peng","year":"2007","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0405","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB\/C mice","author":"Chan","year":"2017","journal-title":"Nephrology (Carlton, Vic)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0410","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1161\/01.CIR.0000147180.87553.79","article-title":"Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-ser-asp-lys-pro and increased phosphorylation of Smad2\/3","volume":"110","author":"Pokharel","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.07.006_bib0415","first-page":"209","article-title":"Myeloid toxicity of cancer treatment","volume":"3","author":"Kurtin","year":"2012","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0420","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury-mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr. Cancer Ther. Rev."},{"key":"10.1016\/j.phrs.2018.07.006_bib0425","first-page":"753","article-title":"The physiological role of the endogenous colony forming units-spleen (CFU-S) inhibitor acetyl-N-ser-asp-lys-pro (AcSDKP)","volume":"3","author":"Frindeland","year":"1989","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2018.07.006_bib0430","first-page":"1077","volume":"17","author":"Monpezatand","year":"1989","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0435","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1749-6632.1991.tb17230.x","article-title":"Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation","volume":"628","author":"Bogden","year":"1991","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.phrs.2018.07.006_bib0440","first-page":"1112","article-title":"Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP","volume":"18","author":"Guigon","year":"1990","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0445","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002770050268","article-title":"In vivo radioprotective effect of AcSDKP on canine myelopoiesis","volume":"74","author":"Deeg","year":"1997","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0450","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2141.1996.d01-1853.x","article-title":"In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation","volume":"94","author":"Watanabe","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0455","first-page":"638","article-title":"Protection of mice against lethal doses of 1 beta-D-arabinofuranosylcytosine by pluripotent stem cell inhibitors","volume":"42","author":"Guigon","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2018.07.006_bib0460","first-page":"251","article-title":"The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells","volume":"20","author":"Bonnet","year":"1992","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0465","first-page":"79","article-title":"Enhanced engraftment of intravenously transplanted hematopoietic stem cells into bone marrow of irradiated mice treated with AcSDKP","volume":"26","author":"Suzuki","year":"1998","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0470","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2003-11-3828","article-title":"Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells","volume":"104","author":"Charrier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2018.07.006_bib0475","first-page":"545","article-title":"Seraspenide (acetylSDKP): phase I-II trial study of inhibitor of hematopoiesis protects against toxicity of aracytine and ifosfamide monochemotherapies","volume":"315","author":"Carde","year":"1992","journal-title":"Comptes rendus de l\u2019Academie des sciences Serie III, Sciences de la vie"},{"key":"10.1016\/j.phrs.2018.07.006_bib0480","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/blood.V82.11.3307.3307","article-title":"Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-ser-asp-lys-pro (seraspenide) on the growth of human CD34+ subpopulations in response to growth factors","volume":"82","author":"Bonnet","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2018.07.006_bib0485","first-page":"898","article-title":"Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line MS-1-T by a tetrapeptide acetyl-N-ser-asp-lys-pro","volume":"17","author":"Lenfant","year":"1989","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0490","first-page":"896","article-title":"Biological activities of tetrapeptide AcSDKP on hemopoietic cell binding to the stromal cell in vitro","volume":"20","author":"Aizawa","year":"1992","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0495","first-page":"273","article-title":"Rossette formation between stromal and hemopoietic cells: a simple assay for the supportive activity of stromal cells","volume":"5","author":"Aizawa","year":"1991","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2018.07.006_bib0500","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1182\/blood-2002-07-2315","article-title":"The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo","volume":"101","author":"Liu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2018.07.006_bib0505","first-page":"204","article-title":"Regulation of hematopoietic stem cell activity by inflammation","volume":"4","author":"Schuettpelzand","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0510","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/01.HYP.0000025880.56816.FA","article-title":"N-acetyl-ser-asp-lys-pro inhibits phosphorylation of Smad2 in cardiac fibroblasts","volume":"40","author":"Pokharel","year":"2002","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0515","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/01.HYP.37.3.827","article-title":"Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts","volume":"37","author":"Rhaleb","year":"2001","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0520","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1172\/JCI109574","article-title":"Mesangial function in ureteral obstruction in the rat. Blockade of the efferent limb","volume":"64","author":"Raij","year":"1979","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2018.07.006_bib0525","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bbrc.2006.02.019","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators","volume":"342","author":"Kanasaki","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2018.07.006_bib0530","doi-asserted-by":"crossref","first-page":"PL221","DOI":"10.1016\/S0024-3205(00)00460-4","article-title":"Acetyl-seryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells","volume":"66","author":"Iwamoto","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2018.07.006_bib0535","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.ASN.0000057544.95569.EC","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of smad pathway in human mesangial cells","volume":"14","author":"Kanasaki","year":"2003","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.phrs.2018.07.006_bib0540","doi-asserted-by":"crossref","first-page":"H2099","DOI":"10.1152\/ajpheart.00592.2004","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo","volume":"287","author":"Wang","year":"2004","journal-title":"Am. J. physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0545","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/01.ATV.0000203510.96492.14","article-title":"Tetrapeptide AcSDKP induces postischemic neovascularization through monocyte chemoattractant protein-1 signaling","volume":"26","author":"Waeckel","year":"2006","journal-title":"Arterioscler. Throm. Vasc. Boil."},{"key":"10.1016\/j.phrs.2018.07.006_bib0550","doi-asserted-by":"crossref","first-page":"9635","DOI":"10.1016\/j.biomaterials.2014.08.011","article-title":"Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels","volume":"35","author":"Zachman","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2018.07.006_bib0555","volume":"2017","author":"Whelton","year":"2017","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0560","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/01.HYP.15.6.547","article-title":"Abnormal pressure natriuresis. A cause or a consequence of hypertension?","volume":"15","author":"Hall","year":"1990","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0565","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/01.HYP.37.2.429","article-title":"Salt sensitivity, pulse pressure, and death in normal and hypertensive humans","volume":"37","author":"Weinberger","year":"2001","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0570","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/HYPERTENSIONAHA.116.07905","article-title":"Research needs to improve hypertension treatment and control in African americans","volume":"68","author":"Whelton","year":"2016","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0575","first-page":"287","article-title":"Obesity hypertension, salt sensitivity and insulin resistance","volume":"10","author":"Rocchini","year":"2000","journal-title":"Nutr. Metab Cardiovasc. Dis.: NMCD"},{"key":"10.1016\/j.phrs.2018.07.006_bib0580","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nature24628","article-title":"Salt-responsive gut commensal modulates TH17 axis and disease","volume":"551","author":"Wilck","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.07.006_bib0585","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/gfq471","article-title":"Inflammation, kidney function and albuminuria in the framingham offspring cohort","volume":"26","author":"Upadhyay","year":"2011","journal-title":"Nephrol., Dial. Transp."},{"key":"10.1016\/j.phrs.2018.07.006_bib0590","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2215\/CJN.03500412","article-title":"Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC","volume":"7","author":"Gupta","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"key":"10.1016\/j.phrs.2018.07.006_bib0595","first-page":"47","article-title":"Hypertension management: an update","volume":"3","author":"Nguyen","year":"2010","journal-title":"Am. Health Drug Benef."},{"key":"10.1016\/j.phrs.2018.07.006_bib0600","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/HJH.0b013e32834103ee","article-title":"Renal protective effects of N-acetyl-ser-asp-lys-pro in deoxycorticosterone acetate-salt hypertensive mice","volume":"29","author":"Rhaleb","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.07.006_bib0605","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1161\/01.CIR.103.25.3136","article-title":"Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension","volume":"103","author":"Rhaleb","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.07.006_bib0610","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2050-7771-2-21","article-title":"Nephrin - a biomarker of early glomerular injury","volume":"2","author":"Kandasamy","year":"2014","journal-title":"Biomarker Res."},{"key":"10.1016\/j.phrs.2018.07.006_bib0615","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00467-007-0633-9","article-title":"Congenital nephrotic syndrome","volume":"24","author":"Jalanko","year":"2009","journal-title":"Pediatr. Nephrol. (Berlin, Germany)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0620","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/HYPERTENSIONAHA.115.05970","article-title":"Renal protective effect of N-acetyl-seryl-aspartyl-lysyl-proline in dahl salt-sensitive rats","volume":"66","author":"Worou","year":"2015","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0625","doi-asserted-by":"crossref","DOI":"10.1093\/ajh\/hpy052","article-title":"Renal protective effects of N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) in obese rats on a High-Salt diet","author":"Maheshwari","year":"2018","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2018.07.006_bib0630","doi-asserted-by":"crossref","first-page":"H984","DOI":"10.1152\/ajpheart.00776.2006","article-title":"Characterization and localization of Ac-SDKP receptor binding sites using 125I-labeled hpp-aca-SDKP in rat cardiac fibroblasts","volume":"292","author":"Zhuo","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0635","first-page":"795","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats","volume":"26","author":"Wang","year":"2010","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.phrs.2018.07.006_bib0640","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/ki.2013.209","article-title":"Thymosin beta4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis","volume":"84","author":"Zuo","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2018.07.006_bib0645","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/HYPERTENSIONAHA.109.144568","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research","volume":"55","author":"Liao","year":"2010","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0650","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1681\/ASN.2011121144","article-title":"MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition","volume":"23","author":"Macconi","year":"2012","journal-title":"J. Am. Soc. Nephrol. : JASN"},{"key":"10.1016\/j.phrs.2018.07.006_bib0655","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000346116","article-title":"Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats","volume":"37","author":"Castoldi","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0660","doi-asserted-by":"crossref","first-page":"696475","DOI":"10.1155\/2014\/696475","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition","volume":"2014","author":"Nagai","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phrs.2018.07.006_bib0665","doi-asserted-by":"crossref","first-page":"9172157","DOI":"10.1155\/2016\/9172157","article-title":"Oral administration of N-acetyl-seryl-aspartyl-lysyl-proline ameliorates kidney disease in both type 1 and type 2 diabetic mice via a therapeutic regimen","volume":"2016","author":"Nitta","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phrs.2018.07.006_bib0670","doi-asserted-by":"crossref","first-page":"29884","DOI":"10.1038\/srep29884","article-title":"Effect of antifibrotic MicroRNAs crosstalk on the action of N-acetyl-seryl-aspartyl-lysyl-proline in diabetes-related kidney fibrosis","volume":"6","author":"Srivastava","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2018.07.006_bib0675","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.phrs.2018.07.006_bib0680","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.intimp.2012.07.023","article-title":"Ac-SDKP ameliorates the progression of lupus nephritis in MRL\/lpr mice","volume":"14","author":"Tan","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0685","doi-asserted-by":"crossref","first-page":"F1146","DOI":"10.1152\/ajprenal.00039.2015","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline: mechanisms of renal protection in mouse model of systemic lupus erythematosus","volume":"308","author":"Liao","year":"2015","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0690","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1681\/ASN.2005040385","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis","volume":"17","author":"Omata","year":"2006","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.phrs.2018.07.006_bib0695","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.biomaterials.2013.12.011","article-title":"Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP","volume":"35","author":"Song","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2018.07.006_bib0700","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1161\/01.HYP.0000100423.24330.96","article-title":"Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension","volume":"42","author":"Peng","year":"2003","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0705","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/01.HYP.0000125013.22494.c5","article-title":"Reduction of cardiac fibrosis decreases systolic performance without affecting diastolic function in hypertensive rats","volume":"43","author":"Cingolani","year":"2004","journal-title":"Hypertension (Dallas, Tex : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0710","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.106.084103","article-title":"Decreased endogenous levels of Ac-SDKP promote organ fibrosis","volume":"50","author":"Cavasin","year":"2007","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0715","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1042\/CS20120619","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats","volume":"126","author":"Gonzalez","year":"2014","journal-title":"Clin. Sci. (London, England : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0720","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.tcm.2010.02.005","article-title":"Mechanisms of cardiac fibrosis in inflammatory heart disease","volume":"19","author":"Kania","year":"2009","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2018.07.006_bib0725","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00424-013-1262-8","article-title":"N-acetyl-ser-asp-lys-pro inhibits interleukin-1beta-mediated matrix metalloproteinase activation in cardiac fibroblasts","volume":"465","author":"Rhaleb","year":"2013","journal-title":"Pflugers Arch.: Eur. J. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0730","doi-asserted-by":"crossref","first-page":"H1176","DOI":"10.1152\/ajpheart.00252.2015","article-title":"Ac-SDKP suppresses TNF-alpha-induced ICAM-1 expression in endothelial cells via inhibition of IkappaB kinase and NF-kappaB activation","volume":"310","author":"Zhu","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0735","doi-asserted-by":"crossref","first-page":"e0190300","DOI":"10.1371\/journal.pone.0190300","article-title":"Ac-SDKP decreases mortality and cardiac rupture after acute myocardial infarction","volume":"13","author":"Nakagawa","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2018.07.006_bib0740","doi-asserted-by":"crossref","first-page":"H1226","DOI":"10.1152\/ajpheart.00305.2007","article-title":"Novel anti-inflammatory mechanisms of N-acetyl-ser-asp-lys-pro in hypertension-induced target organ damage","volume":"294","author":"Sharma","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0745","doi-asserted-by":"crossref","first-page":"H1253","DOI":"10.1152\/ajpheart.00481.2008","article-title":"Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension","volume":"295","author":"Lin","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0750","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/CS20090234","article-title":"Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats","volume":"118","author":"Castoldi","year":"2009","journal-title":"Clin. Sci. (London, England : 1979)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0755","doi-asserted-by":"crossref","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth-regulatory lectin","volume":"296","author":"Liu","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0760","first-page":"1326","article-title":"Scientific letter: Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) and galectin-3 levels in tuberculous pericardial effusion: implications for pathogenesis and prevention of pericardial constriction","volume":"98","author":"Ntsekhe","year":"2012","journal-title":"Heart (British Cardiac Society)"},{"key":"10.1016\/j.phrs.2018.07.006_bib0765","doi-asserted-by":"crossref","first-page":"H1114","DOI":"10.1152\/ajpheart.00300.2011","article-title":"Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats","volume":"303","author":"Nakagawa","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2018.07.006_bib0770","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0022-510X(89)90060-9","article-title":"Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours","volume":"91","author":"Fieschi","year":"1989","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.phrs.2018.07.006_bib0775","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2014.04.025","article-title":"MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat","volume":"271","author":"Ding","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2018.07.006_bib0780","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/STROKEAHA.113.004399","article-title":"Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke","volume":"45","author":"Zhang","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.phrs.2018.07.006_bib0785","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2015.09.017","article-title":"Peptide fragment of thymosin beta4 increases hippocampal neurogenesis and facilitates spatial memory","volume":"310","author":"Kim","year":"2015","journal-title":"Neuroscience"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818302238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818302238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:59:04Z","timestamp":1760911144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818302238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":157,"alternative-id":["S1043661818302238"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.07.006","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}